Ventripoint Diagnostics Ltd., a developer of AI-powered cardiac imaging technology, has announced a strategic collaboration with the Ollie Hinkle Heart Foundation (OHHF) to expand access to advanced heart imaging for children and adults living with congenital and childhood-onset heart disease. The partnership aims to reduce barriers to sophisticated cardiac assessments by combining Ventripoint's VMS+ platform with OHHF's Take Heart Collective Impact Model, which unites healthcare providers, innovators, researchers, families, and social partners including Jovie's Joy and Ella's Umbrella.
Under the collaboration, OHHF will provide initial financial support to place two VMS+ systems within its healthcare partner network. The VMS+ platform uses artificial intelligence and advanced cardiac modeling to generate accurate measurements of heart structure and function from standard echocardiograms, offering clinicians enhanced decision-support capabilities. By delivering insights comparable to MRI but through a more accessible and efficient process, the technology is expected to improve patient monitoring and expand access to advanced cardiac assessment across various heart conditions.
Joe Hostetter, Director of the Congenital Heart Disease Program at Ventripoint Diagnostics, emphasized the importance of accurate and affordable imaging in improving outcomes. "Improving outcomes for people living with heart disease begins with access to accurate, timely, and affordable cardiac imaging," he said. "Together, we have an opportunity to expand access to advanced imaging solutions that help clinicians make more informed decisions and improve care throughout a patient's journey."
The partnership is rooted in the lived experiences of families who have faced challenges in obtaining timely and reliable cardiac information. Katie Nesselbush, Founder of Jovie's Joy and social partner of OHHF, shared her perspective as a mother of a child with dilated cardiomyopathy. "I know firsthand the impossible decisions families can face when trying to get answers about their child's heart," she said. "Technologies like Ventripoint give physicians more information to guide care while reducing barriers and risk for families."
Mark Hinkle, Co-Founder of OHHF, reflected on the loss of his son Ollie at 13 months old and the mission to prevent similar outcomes. "We can't change Ollie's story, and we can't bring Ella back. But we can honor them by ensuring more children have access to the technology, information, and treatment options they never had," he said. "That's the future we're building through the Take Heart Collective Impact Model."
The collaboration represents a model for how innovation and lived experience can work together to address unmet needs in pediatric cardiology. By expanding access to AI-powered imaging, the initiative aims to help clinicians make more informed decisions and provide families with greater confidence in their child's care. The VMS+ platform is already cleared for use in the U.S., Europe, and Canada, and is compatible with ultrasound systems from any vendor.
For more information about Ventripoint and its technology, visit www.ventripoint.com. Details about the Ollie Hinkle Heart Foundation and its Take Heart Collective Impact Model are available at www.ohhf.org.
